I thought the second point in the summary of the AGM Presentation is an intetesting one.
• HIV‐1/BIT225• BIT225‐009 Phase 2 trial provides clear clinical evidence that BIT225 is having a unique effect inindividuals infected with HIV‐1
• Engaged with the right potential partners, with the right legal/commercial deal‐making skills in place
• This is not a fast process; but we are focused an achieving a commercial outcome
• Preclinical Programs
• HBV has promise as a preclinical candidate for joint development.
• BIT225 results validate the platform; potential to facilitate funded developments by partners for“other” viral diseases
• Regional Licensing
• HCV in China remains a significant development opportunity – “cost‐conscious” market combinedwith the high rate of co‐infection HCV & HBV requires different approach than used in the USA
- Forums
- ASX - By Stock
- updates about the deals
I thought the second point in the summary of the AGM...
-
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.30M |
Open | High | Low | Value | Volume |
6.4¢ | 6.6¢ | 4.7¢ | $1.096M | 19.01M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 104497 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 130024 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 104497 | 0.048 |
1 | 25000 | 0.047 |
2 | 24442 | 0.046 |
9 | 571403 | 0.045 |
1 | 250000 | 0.043 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 130024 | 2 |
0.051 | 200000 | 1 |
0.052 | 1552825 | 3 |
0.053 | 285000 | 2 |
0.054 | 139250 | 3 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Don Currie, CEO
Don Currie
CEO
Previous Video
Next Video
SPONSORED BY The Market Online